SEER-2 (Neurotrophic Keratopathy) - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find out if an investigational drug called RGN-259 Thymosin Beta 4 eye drops solution (the study drug) is a safe and effective option for the treatment of neurotrophic keratopathy.

¿Cuál es la Condición que se está estudiando?

Neurotrophic Keratopathy

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Have persistent epithelial defect in one or both eyes
Are diagnosed with neurotrophic keratopathy
Have not had any eye surgery for the last 3 months

For more information about who can be in this study, please contact the study team at DEC-RA@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si decide participar en el estudio, podrá:

Get a random assignment (like a coin flip) to receive either the study drug or a placebo (sterile saline solution)
Visit our clinic at the Duke Eye Center up to 7 times
Keep in touch with the study team for up to 6 weeks

During the study visits, you will have eye exams and vision tests, and you will answer some questionnaires.

Detalles del Estudio

Título Completo

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2) - RGN-NK-302

Investigador Principal